Second-line chemotherapy with fotemustine in temozolomide-pretreated patients with relapsing glioblastoma: a single institution experience

被引:46
|
作者
Scoccianti, Silvia [1 ]
Detti, Beatrice [1 ]
Sardaro, Angela [4 ]
Iannalfi, Alberto [1 ]
Meattini, Icro [1 ]
Leonulli, Barbara Grilli [1 ]
Borghesi, Simona [1 ]
Martinelli, Francesco [3 ]
Bordi, Lorenzo [2 ]
Ammannati, Franco [2 ]
Biti, Giampaolo [1 ]
机构
[1] Univ Florence, Dept Radiotherapy, AOU Careggi, I-50144 Florence, Italy
[2] Univ Florence, Dept Neurol Surg, AOU Careggi, I-50144 Florence, Italy
[3] Univ Florence, Neuroradiol Unit, AOU Careggi, I-50144 Florence, Italy
[4] Univ Bari, Inst Radiol, Dept Internal Med, I-70121 Bari, Italy
关键词
fotemustine; glioblastoma multiforme; high-grade gliomas; relapse; second-line chemotherapy; temozolomide;
D O I
10.1097/CAD.0b013e3283005075
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
To evaluate efficacy and safety of fotemustine chemotherapy in temozolomide (TMZ) pretreated adults with recurrent glioblastoma multiforme (GBM). Primary endpoint was progression-free survival at 6 months. Twenty-seven patients (median age: 56 years; median Karnofsky performance status at progression: 80) with relapsed glioblastoma multiforme underwent fotemustine as second-line chemotherapy after failure of homogeneous postoperative treatment consisting of conformal radiotherapy (60 Gy in 30 fractions) with concomitant TMZ (75 mg/m(2) per day), followed by six courses of TMZ (1150-200 mg/m(2) for 5 days every 28 days). Patients were assigned to Radiation Therapy Oncology Group recursive partitioning analysis classes for gliomas. After MRI-proven tumor relapse or progression, all patients underwent chemotherapy with fotemustine, given intravenously 100 mg/m(2) every week for 3 consecutive weeks (induction phase) and then every 3 weeks (maintenance phase). Adequate liver, renal, and bone marrow functions were required. Toxicity grading was based on the National Cancer Institute's Common Toxicity Criteria (version 2.0). Response to treatment was assessed on MacDonald criteria. According to an intention-to-treat-analysis, data on all enrolled patients were included in statistical analysis. Eight partial responses (29.6%) and five cases of stable disease (18.5%) were observed. Median time to. progression was 5.7 months. Progression-free survival at 6 months was 48.15%. Median survival from the beginning of fotemustine chemotherapy was 9.1 months. Median survival from diagnosis of glioblastoma was 21.2 months. Toxicity was manageable and mainly hematological (grade 3 thrombocytopenia: three cases; grade 4 leukopenia: one case). Fotemustine has shown therapeutic efficacy as single-drug second-line chemotherapy in treatment of TMZ pretreated patients.
引用
收藏
页码:613 / 620
页数:8
相关论文
共 50 条
  • [1] A new schedule of fotemustine in temozolomide-pretreated patients with relapsing glioblastoma
    Addeo, Raffaele
    Caraglia, Michele
    De Santi, M. Serena
    Montella, Liliana
    Abbruzzese, Alberto
    Parlato, Ciro
    Vincenzi, Bruno
    Carraturo, Marco
    Faiola, Vincenzo
    Genovese, Michele
    Cennamo, Gregorio
    Del Prete, Salvatore
    [J]. JOURNAL OF NEURO-ONCOLOGY, 2011, 102 (03) : 417 - 424
  • [2] A new schedule of fotemustine in temozolomide-pretreated patients with relapsing glioblastoma
    Raffaele Addeo
    Michele Caraglia
    M. Serena De Santi
    Liliana Montella
    Alberto Abbruzzese
    Ciro Parlato
    Bruno Vincenzi
    Marco Carraturo
    Vincenzo Faiola
    Michele Genovese
    Gregorio Cennamo
    Salvatore Del Prete
    [J]. Journal of Neuro-Oncology, 2011, 102 : 417 - 424
  • [3] Erratum to: A new schedule of fotemustine in temozolomide-pretreated patients with relapsing glioblastoma
    Raffaele Addeo
    Michele Caraglia
    M. Serena De Santi
    Liliana Montella
    Alberto Abbruzzese
    Ciro Parlato
    Bruno Vincenzi
    Marco Carraturo
    Vincenzo Faiola
    Michele Genovese
    Gregorio Cennamo
    Salvatore Del Prete
    [J]. Journal of Neuro-Oncology, 2011, 102 (3) : 425 - 425
  • [4] Second-line chemotherapy with bevacizumab and fotemustine in temozolomide-pretreated patients with recurrent grade III gliomas: a phase II study
    Franchino, F.
    Magistrello, M.
    Pellerino, A.
    Trevisan, E.
    Ruda, R.
    Soffietti, R.
    [J]. EUROPEAN JOURNAL OF NEUROLOGY, 2015, 22 : 72 - 72
  • [5] Second-line chemotherapy with dacarbazine and fotemustine in nitrosourea-pretreated patients with recurrent glioblastoma multiforme
    Fazeny-Dörner, B
    Veitl, M
    Wenzel, C
    Piribauer, M
    Rössler, K
    Dieckmann, K
    Ungersböck, K
    Marosi, C
    [J]. ANTI-CANCER DRUGS, 2003, 14 (06) : 437 - 442
  • [6] High-dose fotemustine in temozolomide-pretreated glioblastoma multiforme patients A phase I/II trial
    Marinelli, Alfredo
    Lamberti, Giuseppe
    Cerbone, Luigi
    Cordua, Nadia
    Buonerba, Carlo
    Peluso, Gianfranco
    Di Lorenzo, Giuseppe
    De Placido, Sabino
    [J]. MEDICINE, 2018, 97 (27)
  • [7] New frontiers in second-line treatment of Glioblastoma: Re-irradiation in combination with Fotemustine A single institution experience.
    Marin, Alicia
    Buchser, David
    Martin, Margarita
    Lopez, Mario
    Fernandez, Laura
    Cerezo, Laura
    Murillo, M. Teresa
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [8] SALVAGE CHEMOTHERAPY WITH BEVACIZUMAB AND FOTEMUSTINE IN TEMOZOLOMIDE-PRETREATED PATIENTS WITH RECURRENT GRADE III GLIOMAS: A PHASE II STUDY
    Franchino, F.
    Magistrello, M.
    Pellerino, A.
    Nicolotto, E.
    Garbossa, D.
    Bertero, L.
    Trevisan, E.
    Ruda, R.
    Soffietti, R.
    [J]. NEURO-ONCOLOGY, 2016, 18 : 56 - 56
  • [9] Low-dose Fotemustine as Second-line Chemotherapy for Recurrent Glioblastoma Multiforme
    De Felice, Francesca
    Bulzonetti, Nadia
    Musio, Daniela
    D'Elia, Alessandro
    Salvati, Maurizio
    Tombolini, Vincenzo
    [J]. ANTICANCER RESEARCH, 2013, 33 (09) : 4013 - 4016
  • [10] Safety of second-line chemotherapy with non-conventional Fotemustine schedule in recurrent high grade glioma: a single institution experience
    Ferrari, D.
    Simonetti, G.
    Botturi, A.
    Gaviani, P.
    Lamperti, E.
    Mea, E.
    Silvani, A.
    Salmaggi, A.
    [J]. EUROPEAN JOURNAL OF NEUROLOGY, 2012, 19 : 761 - 761